Holen Sie sich die Stockscreener-App
3.545
3.70%
-0.105
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com India
CytomX at Wells Fargo conference: epcam bet and cash strength - Investing.com
CTMXCytomX Therapeutics Inc Revenue Breakdown - Finviz
CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan
FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com Canada
FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com India
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - finance.yahoo.com
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ('Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - The Manila Times
CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan
Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan
CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com
CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - MarketBeat
MSN Money - MSN
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha
CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa
CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK) - The Globe and Mail
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results - MarketBeat
CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside - TradingView
State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight - GuruFocus
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... - Yahoo Finance
CytomX Therapeutics secures $37M from Regeneron amid Q2 revenue miss - scanx.trade
CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises - TradingKey
CytomX Therapeutics Q2 Earnings Call Highlights - marketbeat.com
CTMX Looks 1148.1% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends - Investing.com
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is CytomX Therapeutics Inc (CTMX) Facing Financial Headwinds Aft - GuruFocus
CytomX Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - The Manila Times
CytomX enrolls 113 patients; next colorectal cancer trial planned - Stock Titan
CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash - TradingView
CytomX Therapeutics 2Q 2026: Revenue $1.42M, EPS $(0.09) — 10-Q Summary - TradingView
Press Release: CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - Moomoo
CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO - Stock Titan
CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report - Stock Titan
Bank of America (NYSE: BAC) discloses 7.0% ownership stake in CytomX (CTMX) - Stock Titan
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - The Manila Times
Press Release: CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - Moomoo
InvestingPro’s Fair Value predicted 46% drop in CytomX stock By Investing.com - Investing.com
BlackRock, Inc. Adds to CytomX Therapeutics Inc (CTMX) Stake -- Shares Look 1007% Overvalued on GF Value - GuruFocus
Form 4 CytomX Therapeutics Inc For: 31 July By Investing.com - Investing.com Nigeria
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
CytomX Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call - Quiver Quantitative
Ally Bridge Group NY LLC Makes New $4.23 Million Investment in CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics, Inc. $CTMX Stake Lifted by Elmind Capital LP - MarketBeat
BlackRock (CTMX holder) discloses 7.6% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX appoints Charles Fuchs to board of directors By Investing.com - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):